| Trial ID: | L4028 |
| Source ID: | NCT05418946
|
| Associated Drug: |
Dapagliflozin 10mg
|
| Title: |
The Effects of Dapagliflozin in Normal Clinical Practice in T2D
|
| Acronym: |
PRECARE
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Dapagliflozin 10mg
|
| Outcome Measures: |
Primary: Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment, From baseline to 4 months | Secondary: Assessment of the change in fasting glycemic control (mg/dl), From baseline to 4 months|Evaluation of Body Mass Index (BMI) (kg/m2), From baseline to 4 months|Evaluation of hip and waist circumferences (cm), From baseline to 4 months|Evaluation of systolic and diastolic blood pressure (mmHg), From baseline to 4 months|Evaluation of glomerular filtration rate (GFR) (ml/min/1.73m2), From baseline to 4 months|Evaluation of albuminuria (mg/g creatinine), Albuminuria will be assessed as albumin to creatinine ratio (ACR) which is obtained from the ratio of urinary protein concentration to creatinine in spot urine, From baseline to 4 months
|
| Sponsor/Collaborators: |
Sponsor: University of Milan
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1400
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-06
|
| Completion Date: |
2022-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-06-14
|
| Locations: |
ASST FBF Sacco, Milan, 20157, Italy
|
| URL: |
https://clinicaltrials.gov/show/NCT05418946
|
